This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca PLC (AZN.L) – After the share price plummeted 16% on Thursday, its Imfinzi cancer drug has been granted breakthrough therapy designation by US FDA for patients with locally-advanced unrespectable non-small cell lung cancer. Closing price 4481.00p (Reuters)
British American Tobacco (BATS.L) - Said on Friday it was not surprised by the U.S. FDA announcement that it plans to reduce nicotine levels in cigarettes, a move which saw the share price fall as much as 14% shortly before the close. Closing price 4960.00p (Reuters)
HSBC Holdings (HSBA.L) – Q2 profit beats analysts’ estimates, having risen 13% YoY to $6bn, as outgoing CEO Stuart Gulliver boosted revenue while also trimming costs. The lender said it will spend up to $2bn buying back stock. Closing price 743.60p (Bloomberg)
Mitie Group PLC (MTO.L) - Britain's FRC is investigating any potential breaches in Deloitte's audits of two annual financial statements from the outsourcing company that issued a string of profit warnings last year. Closing price 271.20p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| AstraZeneca | AZN | 3.6% | 3.9% | -0.2% |
| Barclays | BARC | -1.7% | 2.5% | -2.9% |
| BT | BT.A | -1.8% | -0.9% | -4.7% |
| Int. Cons. Airlines | IAG | -0.1% | 3.4% | -1.9% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research